How Many Abaxis, Inc. (NASDAQ:ABAX)’s Analysts Are Bullish?

May 27, 2018 - By Richard Conner

Abaxis, Inc. (NASDAQ:ABAX) LogoInvestors sentiment decreased to 1.27 in Q4 2017. Its down 0.05, from 1.32 in 2017Q3. It turned negative, as 12 investors sold Abaxis, Inc. shares while 40 reduced holdings. 25 funds opened positions while 41 raised stakes. 21.66 million shares or 0.81% less from 21.83 million shares in 2017Q3 were reported.
Voya Mgmt Limited accumulated 10,334 shares. Moreover, Teachers Retirement Sys Of The State Of Kentucky has 0.01% invested in Abaxis, Inc. (NASDAQ:ABAX) for 8,600 shares. Mason Street Advsrs Ltd Llc accumulated 5,903 shares. Raymond James Associates invested in 0.01% or 122,922 shares. C M Bidwell & Assocs has invested 0% of its portfolio in Abaxis, Inc. (NASDAQ:ABAX). Kayne Anderson Rudnick Invest Mgmt Lc invested in 3.66 million shares or 1.47% of the stock. Stifel Corp has invested 0% in Abaxis, Inc. (NASDAQ:ABAX). Atria Investments Limited Liability Corporation owns 0.02% invested in Abaxis, Inc. (NASDAQ:ABAX) for 6,181 shares. Neuberger Berman Limited Liability Com has 0% invested in Abaxis, Inc. (NASDAQ:ABAX) for 20,254 shares. Ameriprise reported 0% in Abaxis, Inc. (NASDAQ:ABAX). Wesbanco Financial Bank Inc, West Virginia-based fund reported 5,500 shares. Employees Retirement Association Of Colorado has invested 0% in Abaxis, Inc. (NASDAQ:ABAX). Regions Fincl has 33,680 shares. 6,884 are owned by Aperio Group Limited Liability. Northern Trust Corp has invested 0% in Abaxis, Inc. (NASDAQ:ABAX).

Since January 30, 2018, it had 0 insider buys, and 11 insider sales for $4.52 million activity. The insider SINGH PRITHIPAL sold 2,000 shares worth $140,500. Shares for $304,953 were sold by Henkel Achim. 1,412 shares valued at $98,266 were sold by ARON KENNETH on Tuesday, March 6. Shares for $122,652 were sold by TOCKMAN CRAIG on Wednesday, January 31. $355,327 worth of Abaxis, Inc. (NASDAQ:ABAX) was sold by CASEY MICHAEL D. $689,851 worth of Abaxis, Inc. (NASDAQ:ABAX) shares were sold by WOOD DONALD PETER.

Abaxis, Inc. (NASDAQ:ABAX) Ratings Coverage

Among 8 analysts covering Abaxis (NASDAQ:ABAX), 1 have Buy rating, 1 Sell and 6 Hold. Therefore 13% are positive. Abaxis had 12 analyst reports since November 30, 2017 according to SRatingsIntel. Raymond James upgraded the stock to “Hold” rating in Tuesday, January 9 report. The firm has “Underperform” rating given on Thursday, February 8 by Bank of America. Credit Suisse upgraded the stock to “Hold” rating in Wednesday, May 16 report. The firm has “Buy” rating by Northcoast given on Monday, January 29. The company was maintained on Thursday, January 25 by Stifel Nicolaus. Canaccord Genuity maintained Abaxis, Inc. (NASDAQ:ABAX) rating on Monday, January 29. Canaccord Genuity has “Hold” rating and $65.0 target. The stock of Abaxis, Inc. (NASDAQ:ABAX) earned “Hold” rating by Stephens on Friday, January 26. The firm has “Hold” rating by Stifel Nicolaus given on Friday, April 27. As per Wednesday, May 16, the company rating was downgraded by Sidoti. On Tuesday, January 16 the stock rating was maintained by Canaccord Genuity with “Hold”. Below is a list of Abaxis, Inc. (NASDAQ:ABAX) latest ratings and price target changes.

16/05/2018 Broker: Credit Suisse Rating: Hold Upgrade
16/05/2018 Broker: Sidoti Old Rating: Buy New Rating: Neutral Downgrade
27/04/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Hold Old Target: $57 New Target: $62 Maintain
08/02/2018 Broker: Bank of America Old Rating: Underperform New Rating: Underperform Old Target: $46 New Target: $48 Maintain
29/01/2018 Broker: Northcoast Rating: Buy New Target: $90.0 Maintain
29/01/2018 Broker: Canaccord Genuity Rating: Hold New Target: $65.0 Maintain
26/01/2018 Broker: Stephens Rating: Hold New Target: $60.0 Maintain
25/01/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $57.0 Maintain
16/01/2018 Broker: Canaccord Genuity Rating: Hold New Target: $55.0 Maintain
09/01/2018 Broker: Northcoast Rating: Buy New Target: $72.0 Maintain

The stock decreased 0.01% or $0.01 during the last trading session, reaching $83. About 253,594 shares traded. Abaxis, Inc. (NASDAQ:ABAX) has risen 44.47% since May 27, 2017 and is uptrending. It has outperformed by 32.92% the S&P500.

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide. The company has market cap of $1.90 billion. It operates in two divisions, Medical Market and Veterinary Market. It has a 76.85 P/E ratio. The firm offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents.

More important recent Abaxis, Inc. (NASDAQ:ABAX) news were published by: 247Wallst.com which released: “Are Abaxis Shareholders Getting Enough in the Buyout?” on May 16, 2018, also Digitaljournal.com published article titled: “NASDAQ:ABAX Investor Alert: Investigation of Takeover of Abaxis, Inc. by Zoetis Inc”, Seekingalpha.com published: “Abaxis May Not Receive A New Offer” on May 25, 2018. More interesting news about Abaxis, Inc. (NASDAQ:ABAX) was released by: Nasdaq.com and their article: “Mid-Afternoon Market Update: Blink Charging Rises After Q1 Results; Purple Innovation Shares Slide” with publication date: May 16, 2018.

Abaxis, Inc. (NASDAQ:ABAX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.